Otten, Thomas http://orcid.org/0000-0002-6390-5638
Riemsma, Rob
Wijnen, Ben
Armstrong, Nigel
Stirk, Lisa
Gordon, Caroline
Ramaekers, Bram
Kleijnen, Jos
Joore, Manuela
Grimm, Sabine
Funding for this research was provided by:
National Institute for Health Research
Article History
Accepted: 12 June 2022
First Online: 8 July 2022
Change Date: 4 September 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s40273-023-01315-1
Declarations
:
: All authors have commented on the submitted manuscript and have given their approval for the final version to be published. RR, NA, LS and JK critiqued the clinical-effectiveness data reported and the literature search conducted by the company. CG provided clinical expert opinion on all aspects of this appraisal. SG, BW, BR, TO and MJ critiqued the mathematical model provided and the cost-effectiveness analyses submitted by the company. TO acts as overall guarantor for the article.
: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment Programme. Please visit the HTA programme website for further project information (ExternalRef removed).
: Caroline Gordon co-authored a grant for the Beat-Lupus Trial, funded by Versus Arthritis, with Principal Investigator (PI) Michael Ehrenstein at University College London, which assessed belimumab (from GSK) after rituximab in SLE, but received no funding herself. Thomas Otten, Rob Riemsma, Ben Wijnen, Nigel Armstrong, Lisa Stirk, Bram Ramaekers, Jos Kleijnen, Manuela Joore, and Sabine Grimm have no conflicts of interest to declare.
: All authors contributed to the study conception and design and all authors were involved with the work of the ERG. The first draft of the manuscript was written by Thomas Otten and all authors had the chance to comment on previous versions of the manuscript. The author contributions for each author are described in the attached authorship forms.
: Not applicable.
: Not applicable.
: Not applicable.